Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 6,000 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the sale, the director directly owned 384,682 shares of the company’s stock, valued at approximately $73,281,921. This trade represents a 1.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ remained flat at $186.95 during trading hours on Friday. 695,901 shares of the company’s stock traded hands, compared to its average volume of 824,700. The firm has a fifty day simple moving average of $177.03 and a 200 day simple moving average of $161.48. The company has a market capitalization of $11.51 billion, a P/E ratio of -31.31, a PEG ratio of 0.34 and a beta of 0.23. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $198.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the firm earned $6.51 earnings per share. The business’s revenue was up 8.1% compared to the same quarter last year. Research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP increased its position in shares of Jazz Pharmaceuticals by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after purchasing an additional 298,815 shares during the last quarter. Capital World Investors increased its position in Jazz Pharmaceuticals by 4.4% during the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock worth $453,322,000 after acquiring an additional 111,735 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after purchasing an additional 191,637 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Jazz Pharmaceuticals by 8.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after acquiring an additional 145,865 shares during the period. Finally, Franklin Resources Inc. increased its holdings in Jazz Pharmaceuticals by 164.0% in the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after buying an additional 1,129,995 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on JAZZ. Bank of America increased their target price on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Truist Financial upgraded Jazz Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Piper Sandler lifted their price objective on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Royal Bank Of Canada lifted their price target on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $215.38.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.